Maurer Christian, Martel Samuel, Zardavas Dimitrios, Ignatiadis Michail
Clinique d'Oncologie Médicale, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany.
Clinique d'Oncologie Médicale, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Département d'hémato-oncologie, CISSS Montérégie centre/Hôpital Charles Lemoyne, centre affilié de l'Université de Sherbrooke, Greenfield Park, QC, Canada.
Breast. 2017 Aug;34:1-11. doi: 10.1016/j.breast.2017.04.007. Epub 2017 Apr 24.
Estrogen receptor positive (ER+) and HER2-negative (HER2-) breast cancer (BC) is the most common BC subtype, defined by expression of the ER and absence of HER2 amplification. Endocrine treatment (ET), aiming at therapeutic blockade of ER signaling, represents the therapeutic mainstay for patients with both early and advanced disease. Despite its wide therapeutic efficacy, ET fails for a proportion of ER+, HER2- BC patients with early disease who develop endocrine resistance, resulting in disease recurrence. Endocrine resistance occurs almost invariably in patients with metastatic disease. Recently, increasing understanding of the molecular mediators of endocrine resistance has been achieved. This review focuses on the molecular mechanisms mediating endocrine resistance, on molecularly targeted agents to overcome or delay it, and potential predictive biomarkers for accurate patient stratification.
雌激素受体阳性（ER+）且人表皮生长因子受体2阴性（HER2-）的乳腺癌（BC）是最常见的乳腺癌亚型，由ER的表达和HER2扩增的缺失所定义。内分泌治疗（ET）旨在对ER信号进行治疗性阻断，是早期和晚期疾病患者的主要治疗手段。尽管其治疗效果广泛，但ET对一部分患有早期疾病且发生内分泌抵抗导致疾病复发的ER+、HER2-乳腺癌患者无效。内分泌抵抗几乎总是发生在转移性疾病患者中。最近，人们对内分泌抵抗的分子介质有了越来越多的了解。本综述重点关注介导内分泌抵抗的分子机制、克服或延缓内分泌抵抗的分子靶向药物以及用于准确患者分层的潜在预测生物标志物。
